Statistical analyses
MAY
Efficacy analyses were performed on the intention-to-treat population, defined as all randomized patients. Patients who received at least one dose of study drug were included in safety analyses. This manuscript presents data from Japanese patients in the control and veliparib-throughout study arms, because the comparison between these two arms was the primary objective of the overall trial. The cutoff date for data presented in this manuscript was May 3, 2019.Progression-free survival was estimated using Kaplan–Meier methodology, and progression-free survival was compared between the control and veliparib-throughout treatment arms using the log-rank test. Unless otherwise noted, statistical significance was determined by a one-sided 